SYNCONA

Syncona

February 2025

Synconaltd.com

Cautionary statement

This presentation has been prepared and published solely for informational purposes. Nothing contained in this presentation is intended to constitute an offer, invitation or inducement to engage in an investment activity.

In this statement, "presentation" means this document together with any oral presentation, any question or answer session and any written or oral material discussed or distributed alongside or in connection with this document.

In making this presentation available, neither Syncona Limited ("Syncona"), Syncona Investment Management Limited ("SIML"), nor any affiliates, agents, directors, managers and advisers of Syncona and/or SIML (together "representatives") makes any recommendation to purchase, sell or otherwise deal in shares in Syncona or any other securities or investments and you should neither rely nor act upon, directly or indirectly, any of the information contained in this presentation in respect of such investment activity. This presentation has not been approved by an authorised person or by any supervisory or regulatory authority.

This presentation speaks as of its date and the information and opinions it contains are subject to change without notice. Neither Syncona nor SIML nor any of their representatives are under any obligation to update or keep current the information contained in this presentation.

The information and opinions contained in the presentation do not purport to be comprehensive. This presentation has not been independently verified. No representation, warranty or other assurance, express or implied, is or will be made in relation to, and no responsibility is or will be accepted by Syncona or SIML or their representatives as to the accuracy, correctness, fairness or completeness of, the information or opinions contained in this presentation. Syncona, SIML and their representatives accept no liability whatsoever for any loss or damage howsoever arising from any use of this presentation or its content or otherwise arising in connection with it.

The presentation may contain "forward-looking statements" regarding the belief or current expectations of Syncona, SIML and their representatives about the financial condition, results of operations and business of Syncona, SIML and Syncona's portfolio of investments. Such forward-looking statements are not guarantees of future performance. Rather, they speak only as of the date of this presentation, are based on current views and assumptions and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Syncona and SIML and are difficult to predict, that may cause the actual results, performance, achievements or developments of Syncona, SIML, Syncona's current or future investments or the industry in which it operates to differ materially from any future results, performance, achievements or developments expressed or implied from the forward-looking statements.

In particular, many companies in the Syncona portfolio are conducting scientific research and clinical trials where the outcome is inherently uncertain and there is significant risk of negative results or adverse events arising. In addition, many companies in the Syncona portfolio have yet to commercialise a product and their ability to do so may be affected by operational, commercial and other risks.

Any target return of Syncona referred to in this presentation is based on performance projections produced by Syncona, SIML and their representatives to the best of their knowledge and belief. It is a target only and therefore subject to change. There is no guarantee that any target return of Syncona can be achieved and past or targeted performance is no indication of current or future performance or results. There can be no assurance that the strategy described in this presentation will meet its objectives generally, or avoid losses.

This presentation is not for publication, release or distribution, directly or indirectly, in nor should it be taken or transmitted, directly or indirectly into, any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction. The distribution of this presentation outside the United Kingdom may be restricted by law and therefore persons outside the United Kingdom into whose possession this presentation comes should inform themselves about and observe any such restrictions as to the distribution of this presentation.

Syncona seeks to achieve returns over the long term. The timing of positive or negative outcomes is uncertain and investors should be aware that over shorter periods our returns are likely to be volatile. The price of shares in Syncona is determined by market supply and demand, and may be volatile in response to changes in demand and different to the net asset value**.**

Overview of FY2024/25

Rebalanced portfolio and strong execution provides a platform for growth

Performance impacted by share price of Autolus

- NAV of £1.12bn, 179.4p per share, a return of 0.3% in the third quarter and (4.9)% in the financial year to date
- Life science portfolio return of (0.7)% in the third quarter and (9.5)% financial year to date
- Performance predominantly impacted by a decrease in Autolus' share price which has fallen 59% in the financial year to date[1]

Rebalanced, maturing portfolio continues to deliver strong execution

- Autolus' AUCATZYL® (obe-cel) received marketing approval from the US FDA in November
- Three key value inflection points delivered by our later stage companies in the year to date; these derisking events validate the progress of these companies towards delivering their future potential, with the potential to drive significant NAV growth over time

Disciplined capital allocation and deployment

- Reflecting successful financing rounds with external investors, capital deployment is expected to be below or at the lower end of guidance of £150-200m; £90m deployed financial year to date
- An additional £15m allocated to the share buyback in November, recycling most of the proceeds from the partial realisation of Autolus and taking total allocation to share buybacks to £75m, underscoring confidence in the portfolio and its potential

Confidence in the path to our NAV target of £5bn by 2032

- Delivery of expected key value inflection points by the end of CY2027 has the potential to drive significant NAV growth
    - Two key value inflection points by the end of CY2025, with a further five expected before the end of CY2027

Well positioned for improving market conditions

- Macro environment is improving with softening inflation and interest rate cuts

1. To end of December 2024

SYNCONA

Market environment



Biotech markets are recovering

Three convergent forces are providing us with a steady path out of a challenging market

A healthier biotech sector

- Now coming to the end of a significant period of restructuring and consolidation, which has led to a biotech market with healthier fundamentals and higher quality companies
- The best science and business have survived and valuations have been corrected
- Late-stage assets led the public and private market recovery, with many being acquired

Improving macroeconomic conditions

- Softening inflation and falling interest rates will provide tailwinds but uncertainty remains
- Cost of capital has come down, which is an essential element for a return to growth
- With this, the private financing environment has improved, underlined by the recent delivery of a number of successful syndicated financings across the Syncona portfolio

An upcoming patent cliff for pharma

- Pharma are facing a patent cliff of over $350bn by 2030[1] and have >$1.5tn in deal capacity
- Pharma have been focused on later-stage assets but the pool of sizeable targets has shrunk after a spate of M&A up to H1 24. Recently we have seen pharma look at earlier stage assets
- The need to buy will drive M&A activity and recycle capital into the biotech sector

Inflation rates across EU/UK/US (2014-2024)[2]



Worldwide Sales at Risk from Patent Expiration (2016-2030)[1]

1. Evaluate Pharma / Stifel Healthcare: Biopharmaceutical Outlook for 2025 2. Bloomberg. Based on consumer prices

SYNCONA

A rebalanced and maturing portfolio



Our NAV Growth Framework

Significant value can be accessed at late-stage clinical development

Operational build

- Clearly defined strategy and business plan
- Leading management team established

Emerging efficacy data

- Clinical strategy defined
- Initial efficacy data from Phase I/II in patients

Definitive data

- Significant clinical data shows path to marketed product
- Moving to pivotal trial and building out commercial infrastructure

On the market

- Commercialising product
- Revenue streams

Key exits[1]

neogene THERAPEUTICS
1.1x
£15m proceeds
(2023)

GYROSCOPE A Novartis Company
2.9x
£325m proceeds
(2022)

nightstar THERAPEUTICS
4.5x
£256m proceeds
(2019)

BLUE EARTH DIAGNOSTICS
9.9x
£351m proceeds
(2019)

1. Returns since 2012, reflects original Syncona Partners capital invested where applicable. Returns since Syncona merged with BACIT in December 2016, are: Neogene 1.1x, Gyroscope 2.9x, Nightstar 3.5x, Blue Earth 3.9x. All multiples reflect up front proceeds. Exits excludes Clade which has not been fully realised, with Syncona continuing to hold shares in Century

We have rebalanced to a more mature portfolio

We have a strategic portfolio of 14 companies at different stages of the clinical development pathway



Portfolio rebalanced towards later-stage companies with increased diversification



- **7%** Commercial (1 company)
- **17%** Late-stage clinical (1 company)
- **43%** Clinical stage (4 companies)
- **33%** Pre-clinical (8 companies)

- **7%** On the market
- **17%** Moving towards the market
- **35%** Moving towards definitive data
- **33%** Moving towards emerging efficacy data
- **8%** Moving towards operational build



1

- **3** Cell therapy
- **3** Gene therapy
- **4** Small molecules
- **3** Biologics

67.4% of portfolio is clinical, late-stage clinical or commercial stage

1. Excluding Slingshot, the Syncona Accelerator. 2. Clade is not yet fully realised, with Syncona retaining shares in Century Therapeutics as part of the acquisition

Driving value through the delivery of KVIPs

Material de-risking events with the potential to drive significant NAV growth

- Key value inflection points are material de-risking events for a portfolio company that have potential to drive significant NAV growth for Syncona
- These milestones can also enable companies to access significant capital, including through financings and IPOs, which may take place at valuation uplifts
- Primarily, key value inflection points are the delivery of emerging efficacy or definitive data, with the latter typically being more valuable
- The delivery of emerging efficacy data and subsequent milestones increasingly builds intrinsic value in a company

Illustrative value appreciation through delivery of KVIPs



3.9x
Aggregate multiple of cost from Syncona's five exits[2]

1. Biologics License Application 2. Reflects upfront proceeds

*Illustrative

Potential from our most mature private portfolio companies

Beacon, Spur and iOnctura to deliver KVIPs by the end of 2027

iONCTURA

Lead programme (roginolisib – first-in-class asset)

- Uveal melanoma is the most common form of eye tumour, with over 7,000 new cases of uveal melanoma annually globally[1]
- Once metastasised (50% of patients) median overall survival is approximately one year[2]
- Data released to date from the Phase Ib trial demonstrates long-term safety and emerging efficacy

Upcoming entry into Phase II trial

SPUR

Lead programme (FLT201 – first-in-class asset)

- Gaucher disease is a disorder caused by the build-up of fatty substances in certain organs, particularly the spleen and liver
- c.18,000 Gaucher disease type 1 patients in the US, UK, EU and Israel[3]
- No substantial advances in treatment in the last two decades
- Presented positive data in October demonstrating long-lasting potential of FLT201 up to 15 months post-dosing (KVIP)
- Additional positive data was presented in February 2025
  - Maintenance of normal haemoglobin levels (Phase III primary endpoint)
  - Durable reductions in lyso-Gb1 (potential endpoint for accelerated approval)
  - Also announced successful End of Phase II meeting with the FDA

Expected to enter Phase III trial in H2 CY2025

beacon therapeutics

Lead programme (AGTC-501 – first-in-class asset)

- XLRP is a genetic disease that causes blindness in men
- >20,000 XLRP patients in US/Europe[4]
- Patients are legally blind by a median age of 45
- Presented positive 24-month interim safety and efficacy data from its Phase II SKYLINE trial in October, demonstrating durable efficacy profile of AGTC-501 (KVIP), and three-month data from Phase II DAWN trial in December (KVIP)

Entered Phase II/III trial in CY2024

Clinical → **Late-stage clinical**

1. iOnctura estimate. 2. iOnctura estimate 3. Spur estimate. 4. Daiger SP. Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol

Peer groups for most mature private companies

Beacon, Spur and iOnctura expected to publish key value inflection points by end of CY2027



Small molecule oncology peer group
Company Valuation = US$141.6m
Syncona ownership = 21.9%
Syncona holding value = US$31.0m (£24.8m)

Rare genetic medicines peer group
Company Valuation = US$239.0m
Syncona ownership = 82.9%
Syncona holding value = US$198.1m (£158.3m)

Ophthalmology genetic medicines peer group
Company Valuation = US$366.0m
Syncona ownership = 41.5%
Syncona holding value = U$151.7m (£121.2m)[1]

Syncona team analysis, data does not represent a forecast. Outliers are excluded from the graphs but included in the calculations. Peer set included on slide 45. 1 – Also includes discounted valuation of Beacon milestone payments

Diversified and maturing portfolio

14 strategic portfolio companies at different stages of development

Portfolio increasingly weighted towards clinical and late-stage clinical development

- Beacon has commenced its pivotal Phase II/III trial whilst Spur will be entering a Phase III trial in H2 CY2025

Significant period of execution across the portfolio

- Eight capital access milestones achieved in the financial year to date and three key value inflection points delivered
  - Beacon 24-month data from Phase II SKYLINE trial in XLRP
  - Beacon 3-month data from Phase II DAWN trial in XLRP
  - Spur data from Phase I/II Gaucher disease trial
- Autolus received marketing approval from the US FDA for AUCATZYL® (obe-cel)

slingshot

SYNCONA

Slingshot - The Syncona Accelerator

A capital efficient way to invest in the next frontier of innovation

Accelerating exceptional academic science towards clinical development with £12.5m commitment

- Slingshot will accumulate and develop multiple pre-clinical programmes under one pipeline
- These programmes will be accelerated along the development pathway towards the clinic
- High quality management team with Syncona Managing Partner Edward Hodgkin appointed Executive Chair, with Executive Partner Richard Wooster appointed as Slingshot's Chief Scientific Officer
- This structure provides a capital efficient and de-risked way to gain more exposure to the returns available from translating highly innovative science into promising biotech assets
- First pipeline programme, Apini, is a small molecule programme focused on inflammatory disease identified from the University of Manchester

- Apini stems from the work of Professor Sam Butterworth, who has 20 years' experience in drug discovery and medicinal chemistry projects

The Slingshot model

- Programmes are identified from world-leading academic institutions in the UK, US and Europe
- Academics are then able to access development expertise that is rarely available for single early-stage programmes, alongside centralised resource, funding and operational support
- This creates a variety of paths to take medicines to the clinic and ultimately to patients



Rigorous approach to capital allocation

Capital pool central to delivery of strategy

We are funded to the delivery of all of our expected key value inflection points

£90m deployed into the life science portfolio in the financial year; capital pool of £344.8m

- 63% of capital pool committed to our existing portfolio and operational costs (including share buybacks), with 23% allocated to underwriting further KVIPs
- Additional capital is allocated to driving broader portfolio milestones and new investments
- 12-24 months of funding allocated to cash and Treasury Bills, with the capital pool returning 3.2%
- A further £35m allocated to the share buyback year to date, taking total allocation to £75m
- We remain funded to deliver on our KVIPs, whilst retaining capital to drive the broader strategy
- £57.2m shares have now been repurchased at an average 36.6% discount resulting in 4.90p accretion[1]



1. As at 5 February 2025

Capital commitments weighted to clinical assets and assets approaching clinical entry

Continue to apply a rigorous approach to capital allocation

- Six financings closed, with five commitments from Syncona
  - £63.5m committed to Resolution Series B financing
  - £33.5m committed to Beacon in £134m Series B financing
  - £19.9m committed to Purespring in £80m Series B financing
  - Additional £9m committed to Mosaic's Series A financing
  - Launch of Slingshot with £12.5m commitment
- Also secured an additional £10m commitment from Roche Venture Fund to Forcefield's Series A financing

Reflecting successful financing rounds with external investors, capital deployment into the life science portfolio is expected to be below or at the lower end of our guidance of £150.0m to £200.0m for this financial year



Capital commitments weighted towards clinical-stage assets or assets approaching the clinic

Attracting external investment to the portfolio

NAV is robust following recent syndicated financings

Portfolio is now substantially refinanced

- £310.6m of capital raised by portfolio companies in the year to date, with £175.5m raised from external investors
- Including the capital pool, £740.5m (65.9%) of NAV has been priced with reference to a third-party mark since the start of 2022, when the market downturn had fully set in
- Our NAV is robust, providing a strong platform for growth



NAV as at 31 December 2024

1. As 28 Feb 2025

A strong platform for growth

A number of expected key value inflection points

Key de-risking events with the potential to drive significant NAV growth

- Recent key value inflection points achieved by Beacon and Spur which provide strong momentum
- Seven key value inflection points across the porfolio, with two expected before the end of CY2025
- These key value inflection points are not without risk

		CY2025	CY2026	CY2027
On the market	Autolus	Commercial traction following Autolus' US launch of obe-cel in **CY2025**, following FDA regulatory approval		
Definitive data	beacon therapeutics		Data readout from Beacon's pivotal VISTA trial in XLRP in **CY2026**	
	IONCTURA		Data readout from iOnctura's Phase II trial in uveal melanoma in **CY2026**	
	SPUR			Completion of the pivotal stage of its Phase III trial in Gaucher disease in **CY2027**
	RTx		Data readout from Resolution's Phase I/II trial in end-stage liver disease in **CY2026**	
Emerging data	QuellTX	Data readout from Quell's Phase I/II trial in liver transplantation in **CY2025**		
	ANAVEON		Data readout from Anaveon's Phase I/II trial of ANV600 in **CY2026**	

Summary and outlook

Focused on delivering our strategy and driving NAV growth for our shareholders

- Later stage and diversified portfolio continues to execute well and has attracted significant external capital
- Continue to focus capital towards opportunities which are clinical stage or close to clinical entry
- Seven key value inflection points expected by the end of CY2027 with the potential to drive significant NAV growth, with two expected by the end of CY2025
- We believe there is substantial latent value in the portfolio which will support the delivery of £5bn of NAV by 2032
- We are well positioned to benefit from an improving macro environment

Rebalanced portfolio provides a strong platform for growth and underpins confidence in achieving our ten-year targets

10-year targets

Creating or adding

3

new companies a year

based on exceptional science

20-25

companies

targeting top quartile returns

3-5 companies to late-stage development with significant ownership positions

£5bn

Net Assets by 2032

SYNCONA

Appendix 1 – Team

Our platform

Our organisational operating model supports the delivery of our strategy

Senior investment team


Chris Hollowood
CEO


Roel Bulthuis
Managing Partner


Ed Hodgkin
Managing Partner


Elisa Petris
Partner


Magdalena Jonikas
Partner

Broader investment team


Alex Hamilton
Principal


Alessio D'addabbo
Analyst


Alice Renard
Principal


Gonzalo Garcia
Principal


Melina Hoffmann
Associate


Michael Kyriakides
Principal


Nathaniel Dahan
Senior Associate


Pierre Joffrin
Senior Associate


Raghd Rostom
Senior Associate


Sarah Qian
Associate Partner

Executive Partner group


John Tsai
Experienced clinical leader


Hitesh Thakrar
Experienced life sciences fund manager


Rolf Soderstrom
Experienced biotech finance executive


Richard Wooster
Extensive drug discovery experience


Kenneth Galbraith
Chair of SIML Commercial leader

A platform for…

- New opportunities
- Company launch
- Clinical approach
- Regulatory plan
- Commercial strategy

… delivering long-term growth

Leadership team comprises experience from across the business

Responsible for the operational delivery of Syncona's strategic priorities

Chris Hollowood
CEO

- M&A
- Biotech investing
- Board leadership
- Strategy development

Roel Bulthuis
Managing Partner, Head of Investments

- Deal generation and delivery
- Investment banking, VC and business development

Kate Butler
CFO

- Balance sheet management
- Strategic leadership

Edward Hodgkin
Managing Partner

- Executive leadership
- Company building

Harriet Gower Isaac
Head of People

- Process optimisation
- People leadership
- Employee engagement

John Tsai
Executive Partner

- Executive leadership
- Support life science portfolio

Annabel Clark
Head of Corporate Affairs and ESG

- Shareholder relations
- Media communications
- Responsible investment

Strong senior investment team

Responsible for leading the investment team and building the next generation of Syncona companies

Chris Hollowood[1]
CEO
PhD

SPUR · Yellowstone BIOSCIENCES · beacon therapeutics

22 years' experience

Roel Bulthuis[2]
Managing Partner, Head of Investments
MSc, MBA

ANAVEON · RTx · IONCTURA

24 years' experience

Edward Hodgkin[2]
Managing Partner
PhD

RTx · OMass THERAPEUTICS · slingshot · MosaicTX

33 years' experience

Elisa Petris[2]
Partner
PhD

QuellTX · beacon therapeutics · forcefield

16 years' experience

Magdalena Jonikas[2]
Partner
PhD

Kesmalea THERAPEUTICS · OMass THERAPEUTICS · MosaicTX

13 years' experience

Full team details: https://www.synconaltd.com/about-us/our-people/
1 Portfolio company chairman, 2 Portfolio company board member/observer

Appendix 2 – Performance and track record

A track record of significant value creation from exits

£1.3 billion invested to date, generating an IRR of 16.4%, 1.3x invested capital[1]

Exits generated £955m of proceeds, at an aggregate IRR of 73.6% and a 3.9x cost[2]

Blue Earth
- First invested in 2014, sold to Bracco Imaging in 2019
- 83% IRR – 9.9x cost on £351.0m proceeds

Nightstar
- Founded company in 2013, sold to Biogen in 2019
- 71% IRR – 4.5x cost on £255.7m proceeds

Gyroscope
- Founded company in 2016, sold to Novartis in 2022
- 50% IRR – 2.9x cost on £325.3m proceeds

Neogene
- First invested in 2019, sold to AstraZeneca in 2023
- 3% IRR – 1.1x cost on £15.3m upfront proceeds



Returns since Syncona merged with BACIT in December 2016, are: Neogene 1.1x, Gyroscope 2.9x, Nightstar 3.5x, Blue Earth 3.9x.

All financial data at 31 December 2024

1. Includes sales of Nightstar, Blue Earth, Gyroscope and Neogene, upfront consideration of Clade and closure of 14MG and Azeria. Reflects original Syncona Partners capital invested where applicable. All IRR and multiple on cost figures are calculated on a gross basis
2. Includes sales of Nightstar, Blue Earth, upfront proceeds from sale of Gyroscope, upfront proceeds from Neogene and upfront consideration of Clade. Reflects original Syncona Partners capital invested where applicable. All IRR and multiple on cost figures are calculated on a gross basis. 3. Biologics License Application

Building companies with impact

Syncona has generated significant impact across its portfolio since being founded in 2012

Building global leaders

26	Syncona portfolio companies since 2012 foundation
14	Number of companies in the portfolio today
1,000+	Number of employees across Syncona portfolio

Our track record

16.4%	IRR since 2012; 1.3x multiple on cost across whole portfolio[1]
£1.3bn	Syncona capital deployed since 2012
£955m	Generated from five successful exits; 3.9x multiple of cost[2]

Clinical progress

4	Late-stage clinical companies across the portfolio since inception
29	Clinical-stage programmes across the portfolio since inception
20	Number of clinical trials in the portfolio

Patient impact

165k	Patients diagnosed by Blue Earth's product Axumin
8,400	Annual cases of Adult ALL, disease targeted by Autolus' AUCATZYL[3]
6	Diseases with high unmet need targeted by lead programmes in clinical portfolio

1. Includes sales of Clade, Nightstar, Blue Earth, Gyroscope and Neogene and closure of 14MG and Azeria. Reflects original Syncona Partners capital invested where applicable. All IRR and multiple on cost figures are calculated on a gross basis. Since 2016, Syncona's NAV per share has increased from 127.9p to 178.9p, a total return of 5.0% per annum, and the Syncona life science portfolio has delivered an IRR of 12.9% and a 1.3 multiple of cost
2. Includes sales of Clade, Nightstar, Blue Earth, upfront proceeds from sale of Gyroscope and upfront proceeds from Neogene, reflects original Syncona Partners capital invested where applicable. All IRR and multiple on cost figures are calculated on a gross basis. Calculated from our original 2012 founding
3. Autolus corporate presentation

All financials as at 31 December 2024, employee numbers as of March 2024

SYNCONA

Appendix 3 - Portfolio

Commercial | Late-stage clinical | Clinical | Pre-clinical

Portfolio company	Fully diluted ownership %[4]	30 Sep 2024 value £m (fair value)	Net invested/returned in the period £m	Valuation change £m	FX movement £m	31 Dec 2024 value £m (fair value)	Valuation basis (fair value)[1,2,3]	% of NAV
Autolus	9.9%	83.4	(6.6)	(27.4)	4.7	54.1	Quoted	4.8%
beacon therapeutics	41.5%	113[5]	-	0.4	7.8	121.2[5]	PRI	10.8%
SPUR	82.9%	157.5	-	0.8	-	158.3	Cost	14.1%
QuellTX	33.7%	80	-	-	5.5	85.5	PRI	7.6%
ANAVEON	36.9%	35.9	-	-	(0.1)	35.8	PRI	3.2%
IONCTURA	21.9%	25	-	-	(0.2)	24.8	PRI	2.2%
RTx	82.6%	63.6	-	-	-	63.6	Cost	5.6%
purespring	38.1%	51.2	-	-	-	51.2	PRI	4.6%
OMass THERAPEUTICS	28.9%	49.7	-	-	-	49.7	PRI	4.4%
Kesmalea THERAPEUTICS	59.7%	20	-	-	-	20	Cost	1.8%
Yellowstone BIOSCIENCES	60.9%	16.5	-	-	-	16.5	Cost	1.5%
MosaicTX	76.6%	15	-	-	-	15	Cost	1.3%
forcefield	62.6%	10.6	-	-	-	10.6	PRI	0.9%
slingshot	100%	5.6	-	-	-	5.6	Cost	0.5%
Portfolio milestone payments		4.8	-	0.1	0.4	5.3		0.5%
Syncona Investments		60.1	-	0.9	1.4	62.4		5.5%
Capital pool		352.7	(15.6)	2.4	5.3	344.8		30.7%
Total		**1,144.60**				**1,124.4**		100.0%

1. Primary input to fair value of equity holding. 2. The basis of valuation is stated to be "Cost", this means the primary input to fair value is capital invested (cost) which is then calibrated in accordance with our Valuation Policy. 3. The basis of valuation is stated to be "PRI", this means the primary input to fair value is price of recent investment which is then calibrated in accordance with our Valuation Policy. 4. Percentage holding reflects Syncona's ownership stake at the point full current commitments are invested. 5. Total investment interest related to Beacon includes the value of equity held in the company and deferred consideration

SYNCONA

Commercial

Autolus Therapeutics

Leading cell therapy company with lead programme in adult ALL granted approval by the US FDA

Initial investment	2014
Value	£54.1m
Financing stage	NASDAQ
Stage of lead programme	Approved

Investment thesis and company update

- Lead product candidate, for AUCATZYL® (obe-cel), a potentially best-in-class therapy for relapsed refractory for adult acute lymphoblastic leukaemia (ALL), has a competitive profile in B-cell non-Hodgkin's lymphoma (B-NHL) and has potential in autoimmune diseases
- Granted marketing approval by the US FDA in November 2024
- Advanced in-house manufacturing facility ready for commercial launch
- Autolus expects to publish initial data from its Phase I trial of obe-cel in SLE in H1 CY2025

Targeting an area of high unmet need

- Only 30-40% of patients with adult ALL achieve long-term remission with combination chemotherapy, the current standard of care[1]
- obe-cel has the potential to be a best-in-class curative therapy in adult ALL
- Launched a Phase I trial in systemic lupus erythematosus (SLE) in H1 CY2024, a multi-organ systemic autoimmune disease that affects approximately 160K - 320K patients in the US[2]. Initial data from the trial is expected in H1 CY2025

Key data

- Data has demonstrated at 21.5 months median follow up 40% of B-cell ALL patients treated with obe-cel were in ongoing remission without Stem Cell Transplant (SCT) or other therapy[1]

Market opportunity for lead programme

- **Over 8,000 new cases** of adult ALL annually worldwide[1]
- Obe-cel could launch into an expanding ALL market with commercial rollout planned for 2024
- Tecartus® (approved in 2022) is expected to establish CAR-T in adult ALL; sales increased 21% to $107m in the second quarter 2024[3]
- Blincyto®, current market leader, sales increased 41% year-over-year to $1,216 in 2024[4]



1. Autolus corporate presentation 2. Mackensen et al., Nat Med. 2022, Mougiakakos et al. N Engl J Med. 2021, Müller et al. Lancet. 2023, Bergmann et al. Ann Rheum Dis. 2023, Taubman et al. Rheumatology (Oxford). 2023 3. Gilead 4. Amgen

SYNCONA

Late-stage clinical

Beacon Therapeutics

Progressing its pivotal study in X-linked retinitis pigmentosa

Initial investment	2022
Value	£121.2m
Financing stage	Series B
Stage of lead programme	Phase II/III

Investment thesis

- Beacon has a highly attractive gene therapy programme targeting X-linked retinitis pigmentosa (XLRP), a blinding disease
- Clinical data generated by the company so far has been encouraging demonstrating improvements in visual sensitivity sustained for 36 months
- Registrational VISTA trial initiated in H1 CY2024, with data readout expected in CY2026
- Retinal gene therapy is an area where Syncona has significant expertise and XLRP is a disease setting the team knows well from Nightstar experience

Targeting an area of high unmet need

- XLRP is a severe, aggressive, inherited retinal disease
- Disease progression – moves from night blindness to central vision loss and legally blind by median age 45
- Currently no approved treatment options
- Beacon's potentially best-in-class programme is the only late-stage clinical programme that can deliver the full-length missing protein, important for function of both rods and cones



Market opportunity

- >20,000 patients in US/Europe[1]
- Although XLRP accounts for 15% of all cases of retinitis pigmentosa (RP), it is characterised to have the most severe vision loss - with XLRP patients four times more likely to have visual acuity ≤20/200 (legally blind), than those with autosomal dominant RP



1. Daiger SP. Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol

Spur Therapeutics

Developing transformative gene therapies for patients suffering from chronic debilitating diseases

Clinical stage

Initial investment	2015
Value	£158.3m
Financing stage	Taken private
Stage of lead programme	Phase I/II

Investment thesis

- Spur is driving forward two potentially first-in-class gene therapy assets towards late-stage development, including a highly differentiated gene therapy candidate for Gaucher disease type 1, FLT201
- Published compelling initial data demonstrating robust enzyme activity and favourable safety and tolerability

Targeting an area of high unmet need

- Gaucher disease type 1 is a **debilitating, chronic and progressive** disorder
- Affects multiple organs, leading to wide range of symptoms and shortening life span
- Second clinical-stage gene therapy programme in adrenomyeloneuropathy (AMN)
- AMN is a devastating inherited neurodegenerative disease with **no approved treatment**

Market opportunity

- Spur estimates that Gaucher Disease Type 1 has approximately **18,000** patients[1]
- Annual Gaucher market size is **$2bn**[2]

1. Company estimate 2. Global Gaucher's Disease Treatment Market Report and Forecast 2023-2031, Research and Markets. Note: this includes enzyme replacement therapy and substrate replacement therapy

SYNCONA

Clinical stage

Quell Therapeutics

On track to be the first company to deliver engineered Tregs in the liver transplant setting

Initial investment	2019
Value	£85.5m
Financing stage	Series B
Stage of lead programme	Phase I/II

Investment thesis

- Potential to durably reset immune dysregulation with a single treatment, in transplantation, auto-immunity and inflammation
- On track to be the first trial in liver transplantation – a de-risked setting with significant unmet need for patients
- Collaboration with AstraZeneca announced in 2023 with $85m upfront (cash and equity) and potential payments of over $2bn
- Funded through key datasets with strong investor syndicate
- Presented clinical data demonstrates QEL-001 to be safe and well tolerated

Targeting an area of high unmet need

- Current standard of care for prevention of solid organ transplant rejection is life-long immunosuppression which results in an array of serious long-term side effects significantly impacting patient quality of life[1]
- Immunosuppression leaves the patient open to attack by pathogens which cause serious infections
- Immunosuppression can also leave a patient susceptible to developing cancer due to it not being recognised and cleared by the body
- Quell's Treg therapy could save patients from needing life-long immunosuppression

Market opportunity

- 15,000 liver transplants per year across US and Europe[2]

1. https://www.ema.europa.eu/en/clinical-investigation-immunosuppressants-solid-organ-transplantation 2. OPTN/SRTR 2016 Annual Data report: Liver; EDQM Volume 20 2015

Anaveon

Harnessing the power of IL-2 for patients with solid tumours

Clinical stage

Initial investment	2019
Value	£35.8m
Financing stage	Series B
Stage of lead programme	Phase I/II

Investment thesis

- Developing a selective IL-2 receptor agonist with improved administration and toxicity burden
- Company's lead asset ANV600 is in a Phase I/II dose escalation trial
- Pre-clinical data suggests potential of ANV600 to be a best-in-class agent

Targeting an area of high unmet need

- Human Interleukin 2 "IL-2" approved as a medicine for the treatment of metastatic melanoma and renal cancer, but with a cumbersome administration schedule and significant toxicity[1]
- Anaveon anticipates targeting cells expressing PD-1 will have potential application in a range of solid tumours resistant to existing therapies

Market opportunity

- Wide potential utility across multiple oncology indications in wider markets[2]

1. OPTN/SRTR 2016 Annual Data report: Liver; EDQM Volume 20 2015 2. https://seer.cancer.gov/statfacts/html/melan.html 4. GLOBOCAN 2020

iOnctura

Innovative small molecule company developing transformative cancer therapies

Clinical stage

Initial investment	2024
Value	£24.8m
Financing stage	Series B
Stage of lead programme	Phase Ib

Investment thesis

- iOnctura represented an opportunity to invest in a clinical-stage company that has published promising emerging data to date
- Opportunity to drive lead programme through late-stage clinical development
- The PI3K signalling pathway is one of the most commonly dysregulated pathways in cancer
- iOnctura's lead programme, roginolisib, is a **first-in-class, highly selective allosteric inhibitor** of PI3Kδ, with a unique chemical structure and binding mode
- The Syncona team has worked closely alongside iOnctura to consider the broader application of roginolisib

Targeting an area of high unmet need

- Once metastasised (50% of patients) overall survival of uveal melanoma patients drops to **one year**[1]



Roginolisib boosts **tumour targeting cells** and reduces levels of **tumour protecting** cells to boost the fight against **cancer cells**



Market opportunity

- Over **7,000** new cases of uveal melanoma annually worldwide[2]

1. Rantala, 2019. 2. GLOBOCAN 2020

SYNCONA

Pre-clinical stage

Initial investment	2018
Value	£63.6m
Financing stage	Series B

Resolution Therapeutics

Seeking to extend the impact of cell therapy into chronic inflammatory liver disease

Investment thesis

- Resolution is focused on the treatment of chronic liver disease, the only chronic disease still on the rise in Western countries[1]
- Studies have identified a prominent role for macrophages in tissue repair. Pro-restorative macrophages can digest fibrotic scar, modulate the inflammatory response and promote organ repair
- Encouraging clinical data obtained in cirrhotic patients with earlier generation (academic) programme
- Company's lead program is an engineered, autologous macrophage product

Targeting an area of high unmet need

- Cirrhotic patients experience severe "decompensation" episodes as a result of failing liver function
- Decompensation episodes include life-threatening GI bleeding, ascites and coma, all of which contribute to a high cost of treatment and the need for liver transplantation
- Liver transplant, the only therapeutic treatment for chronic liver failure, is associated with high morbidity, mortality and cost, and requires lifetime immunosuppression

Market opportunity

- >500k individuals in the US alone with end stage liver disease[2]



1. Resolution analysis 2. GBD 2017 Cirrhosis Collaborators, Lancet Gastroenterol Hepatol., 2020; Ladner DP., et al. PLoS One, 2024; LEK analysis

SYNCONA

Pre-clinical stage

Initial investment	2020
Value	£51.2m
Financing stage	Series B

Purespring Therapeutics

First company to treat kidney diseases by directly targeting the podocyte with AAV gene therapy

Investment thesis

- Developing a proprietary platform to enable kidney gene therapy
- Targeting the podocyte allows it to directly treat a significant portion of kidney diseases
- We only have a finite number of podocytes in our kidneys: unlike other human cells such as liver cells or skin cells, podocytes do not regenerate over our lifetime
- Injuries to the podocytes lead to issues in the filtration barrier, reducing the kidney's filtration capacity, causing kidney diseases

Targeting an area of high unmet need

- There are currently no curative or disease-modifying therapies
- Current standard of care for end-stage renal disease relies on either dialysis or kidney transplant
- Haemodialysis can cause low blood pressure and leave patients at risk of infection, whilst kidney transplant patients will still need to take lifelong immunosuppression



Market opportunity

- c.4 million patients are on renal replacement therapy[1]
- More than 840 million people globally suffer from chronic kidney disease[2]
- The podocyte is implicated in 60% of renal disease[2]

1. https://www.nature.com/articles/s41581-022-00542-7 2. Purespring analysis

SYNCONA

Pre-clinical stage

Initial investment	2018
Value	£49.7m
Financing stage	Series B

OMass Therapeutics

A platform built to unlock highly validated but inadequately drugged targets, with a focus on immunological and rare diseases

Investment thesis

- Historically, small molecule drug discovery has focused on targets that operate in relative isolation
- Many of the best targets operate within a membrane or an intracellular complex
- To drug these targets, it is necessary to interrogate their full spectrum of physical interactions within the native ecosystem
- OMass' platform seeks to interrogate not just the target, but how it interacts with its native ecosystem to identify new medicines against highly validated but inadequately drugged targets
- Pipeline of small molecule therapeutics including five programs in rare diseases and immunological conditions

Targeting an area of high unmet need

- All of OMass' programmes are in indications with significant unmet medical need
- Programmes include: orphan endocrine disorders, lupus and other IFN-opathies, immunology, inflammatory bowel disease and epilepsy



Market opportunity

- Most advanced programme in orphan endocrine disorders could potentially include several indications with large market sizes
- These include, congenital adrenal hyperplasia (CAH) and in ACTH-dependent Cushing's syndrome
- CAH occurs in about 1 in 13,000-15,000 births[1], and presents a $450m global market opportunity[2]
- Pituitary ACTH-dependent Cushing causes 65 to 70 percent of Cushing syndrome[3].

1. https://www.ncbi.nlm.nih.gov/books/NBK278953/ 2. https://www.marketresearchfuture.com/reports/congenital-adrenal-hyperplasia-market-4946 3. Endocrinol Metab Clin North Am. 1988;17(3):445.

SYNCONA

Pre-clinical stage

Kesmalea Therapeutics

Opportunity to create a new generation of oral drugs addressing diseases through modulating protein homeostasis

Initial investment	2022
Value	£20.0m
Financing stage	Series A

Investment thesis

- Small molecule drug discovery platform focused on protein homeostasis
- Protein homeostasis is the system of maintaining the equilibrium of proteins in the human body. This intricate system is in a constant state of change, with the body continuously synthesising and regulating proteins, whilst removing those which are no longer required (or have mutated) through controlled degradation
- Utilises its small molecule drug discovery platform to address some of the challenges in developing oral therapeutics against targets in areas of high unmet medical need
- Founded by Dr Harry Finch, a world-class chemist and co-inventor of GSK's Serevent™

Targeting an area of high unmet need

- Small perturbations of the human body's natural control mechanism that result in an excess or absence of certain proteins can drive the progression of disease
- Kesmalea aims to counter this dysregulation with novel treatments which restore balance through effective protein degradation or stabilisation
- Its novel approach allows it to overcome the challenges of existing protein degradation and stabilisation technologies, opening the door to previously unavailable oral therapeutics in areas of high unmet medical need

Market opportunity

- Protein degradation has the potential to be broadly applicable across of range of therapeutic areas, including but not limited to oncology, immunology and neurology indications
- Kesmalea will take a targeted approach as it develops its pipeline to ensure its programmes are addressing indications with significant clinical unmet need and ability to leverage Kesmalea's differentiation in oral therapeutics



Yellowstone Biosciences

Pioneering soluble bispecific T-cell receptor (TCR)-based therapies to unlock a new class of cancer therapeutics

Pre-clinical stage

Initial investment	2024
Value	£16.5m
Financing stage	Series A

Investment thesis

- Developing treatments for oncology indications with a high unmet patient need that presents a significant commercial opportunity
- Advancing its lead programme in acute myeloid leukaemia (AML), with pipeline potential across a range of other cancers
- Spun out from the University of Oxford around the pioneering work of Prof. Paresh Vyas, a world leader in haematological oncology
- Support of Syncona launch team has enabled the company to operationalise at pace, accelerating its early development

Targeting an area of high unmet need

- **80%** of all AML patients progress to relapsed/refractory (r/r) status which has **median survival of 3-6 months**, and no universally agreed standard of care for the majority of patients[1]
- An ongoing challenge for the industry has been **identifying frequently expressed antigens** that can be targeted therapeutically across patients, a challenge that Yellowstone's platform overcomes

Market opportunity

- **>40,000** new cases of AML annually across the US and Europe[1]
- Yellowstone's class of therapeutics has the potential to address unmet clinical need in a **broader set of cancers beyond AML,** expanding the market opportunity significantly

1. Yellowstone analysis

SYNCONA

Pre-clinical stage

Initial investment	2022
Value	£15.0m
Financing stage	Series A

Mosaic Therapeutics

Leveraging the unprecedented insights of the genomic revolution to develop targeted therapies for cancer

Investment thesis

- Tumour agnostic drug discovery based upon deep biological understanding of target-disease association, seeking precision oncology drug combinations for biomarker-stratified populations
- Differentiated platform technology leveraging machine learning, patient tumour material and existing chemical matter provides opportunity for improved success rates and potential for accelerated clinical entry

Targeting an area of high unmet need

- Mosaic platform and proprietary technology enables large scale CRISPR and drug screens, supporting drug development against genetically informed targets
- Drug development is hampered by a 90% clinical failure rate[1]

Market opportunity

- Testing all potential drug, target and therapeutic hypotheses is too time consuming and costly; there are over 800 known cancer fitness genes, over 200 cancer types, and over 2,000 known genetic biomarkers

1. Sun D, et al. Why 90% of clinical drug development fails and how to improve it?

Forcefield Therapeutics

Pioneering therapeutics to retain heart function

Pre-clinical stage

Initial investment	2022
Value	£10.6m
Financing stage	Series A

Unmet need in heart disease

- Heart disease is the leading cause of death worldwide
- Acute myocardial infarction (AMI), affects 3 million people worldwide annually[1]
- There has been no significant pharmacological advancement in the treatment for AMI in the past two decades
- 25% of cells in an area of heart containing up to 2-4 billion cells die after heart attack and reperfusion treatment[1]
- Cells are not replaced, leading to further heart attacks, heart failure or death
- Initially a seed investment with Syncona committing £20.0m in a Series A financing, with Roche Venture Fund subsequently committing a further £10m

Forcefield Therapeutics

- Pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes
- Discovered first-in-class cardioprotective proteins that Forcefield is progressing to target AMI



Source: Global Awareness of Myocardial Infarction Symptoms in General Population; Korean Circulation Journal. Forcefield investment thesis to date based upon pre-clinical data

1. Forcefield analysis

Pre-clinical stage

Initial investment	2024
Value	£5.6m

Slingshot Therapeutics

Bridging the gap from academia to drug development

Slingshot model

- Successful programmes are identified from world-leading academic institutions in the UK, US and Europe
- Programmes are supported along the development pathway towards the clinic, leveraging Syncona's expertise creating and building companies from early-stage science
- Creates a variety of paths to take medicines to the clinic



Investment thesis

- A compelling and capital efficient way to gain exposure to the returns available from translating highly innovative science into promising biotech assets
- Allowing Syncona to accelerate exceptional academic science towards clinical entry in a capital efficient way
- Syncona Managing Partner, Edward Hodgkin is Executive Chair, and Executive Partner, Richard Wooster is Slingshot's Chief Scientific Officer
- Advance multiple pre-clinical programmes under one pipeline, supporting the early and efficient de-risking of leading science before clinical entry
- First pipeline programme: Apini, a small molecule inflammatory disease programme identified from the University of Manchester

SYNCONA

Appendix 4 – Additional information

Further information - Peer groups for most mature private companies (slide 11)

Company	Constituents of trading peer group	Constituents of M&A peer group
IONCTURA	Revolution Medicines, Nuvalent, IDEAYA Biosciences, Nurix Therapeutics, Recursion, Relay Therapeutics, Tyra, Monte Rosa Therapeutics, Foghorn Therapeutics, C4 Therapeutics, Acrivon Therapeutics, Nuvectis Pharma, Black Diamond Therapeutics, Prelude Therapeutics, Immuneering	AnHeart Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals, ORM-6151, Kinnjiu Biopharma, Turning Point, Oncoceutics, Forbius, ArQule, Peloton Therapeutics, Loxo Oncology, Ignyta, Tolero, Acerta Pharma
SPUR	Crispr, Intellia, Rocket, Neurogene, RegenxBio, Verve, Taysha, Voyager, UniQure, Editas, Lexeo, Solid Bio, Bluebird Bio	Orchard Therapeutics, Decibel Therapeutics, Akouos, Prevail Therapeutics Inc, AskBio, Audentes Therapeutics, AveXis
beacon therapeutics	RegenxBio, Meira GTx, 4D Molecular Therapeutics, Adverum Biotechnologies	Bota-vec (MeiraGTx), Iveric Bio, Gyroscope Therapeutics, Nightstar Therapeutics, Spark Therapeutics, Ocata